Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing KB105 that is in Phase I/II clinical study for treating patients with deficient autosomal recessive congenital ichthyosis; KB301, which is in Phase I/II clinical stage for treating wrinkles and acne scars; KB407 that is in preclinical stage for cystic fibrosis; and KB104, which is in preclinical stage for netherton syndrome. Its discovery stage product candidates include KB5xx for treating chronic skin diseases, KB3xx to treat aesthetic skin conditions, and KB3xx for other rare lung disease. Krystal Biotech, Inc. was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania.
IPO Year: 2017
Exchange: NASDAQ
Website: krystalbio.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/6/2026 | $309.00 | Neutral → Buy | Citigroup |
| 3/5/2025 | $245.00 | Buy | Jefferies |
| 8/6/2024 | $195.00 → $204.00 | Buy → Neutral | Citigroup |
| 11/20/2023 | $160.00 | Buy | Goldman |
| 10/24/2023 | $100.00 | Overweight | Cantor Fitzgerald |
| 10/12/2023 | $160.00 | Buy | Citigroup |
| 9/7/2023 | $154.00 | Buy | Berenberg |
| 4/18/2023 | $102.00 | Buy | Stifel |
| 2/28/2023 | $79.00 → $124.00 | Neutral → Buy | Goldman |
| 8/25/2022 | $74.00 | Buy → Neutral | Goldman |
Live FDA approvals issued by the Food and Drug Administration and FDA breaking news
For Immediate Release: May 19, 2023 Today, the U.S. Food and Drug Administration approved Vyjuvek, a herpes-simplex virus type 1 (HSV-1) vector-based gene therapy, for the treatment of wounds in patients 6 months of age and older with dystrophic epidermolysis bullosa (DEB) with mutation(s) in the collagen type VII alpha 1 chain (COL7A1) gene. “Vyjuvek is the first FDA-approved gene therapy treatment for DEB, a
Fastest customizable press release news feed in the world
PITTSBURGH, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the "Company") (NASDAQ:KRYS) today announced that the Company will participate in the TD Cowen 46th Annual Health Care Conference on March 3, 2026, in Boston. Company executives will take part in a fireside chat scheduled at 3:10 pm ET and host investor meetings throughout the day. A webcast of the presentation will be available here beginning at 3:10 pm ET on Tuesday, March 3, 2026 and will be posted on the Investors section of the Company's website. About Krystal Biotech, Inc.Krystal Biotech, Inc. (NASDAQ:KRYS) is a fully integrated, commercial-stage, global biotechnology company focused on the discovery, development
$107.1 million in 4Q VYJUVEK revenue and $730.3 million since U.S. launch FDA granted RMAT to KB707 for the treatment of advanced NSCLC and Fast Track Designation to KB111 for the treatment of HHD Strong balance sheet, ending the quarter with $955.9 million in cash and investments PITTSBURGH, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the "Company") (NASDAQ:KRYS) today reported financial results for the fourth quarter and full year ending December 31, 2025 and provided a business update. "In 2025, Krystal made meaningful progress on our mission to serve patients with dystrophic epidermolysis bullosa around the world, while continuing to build the global infrastructure req
PITTSBURGH, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the "Company") (NASDAQ:KRYS) announced today that it will report its fourth quarter and full year 2025 financial results on Tuesday, February 17, 2026, prior to the open of U.S. markets. The Company's management will also host a conference call and webcast at 8:30 am ET on Tuesday, February 17, 2026, to discuss the financial results and provide a business update. Investors and the general public can access the live webcast at: https://www.webcaster5.com/Webcast/Page/3018/53598. For those unable to listen to the live webcast, a replay will be available for at least 30 days on the Investors section of the Company's websi
PITTSBURGH, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the "Company") (NASDAQ:KRYS) announced today that the United States Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to KB707, the Company's redosable immunotherapy designed to drive sustained, localized expression of interleukin-2 and interleukin-12 in the tumor microenvironment, for the treatment of advanced or metastatic non-small cell lung cancer (NSCLC). "The FDA's decision to grant RMAT designation to KB707 reflects both the urgent unmet need for new NSCLC therapies as well as the promising early clinical evidence of efficacy we have observed with inhaled KB707 in
Preliminary 4Q 2025 VYJUVEK net revenue of $106 million to $107 million Robust clinical pipeline with multibillion dollar opportunities and strong balance sheet for sustained growth PITTSBURGH, Jan. 11, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the "Company") (NASDAQ:KRYS) today announced selected preliminary unaudited 2025 financial results, including fourth quarter and full year 2025 VYJUVEK® net product revenue, and outlined the Company's strategic vision to drive the next stage of growth of its rare disease business. These topics will be discussed during the Company's presentation at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco tomorrow, Monday, January 1
Confirmed wild-type CFTR delivery and expression in conducting airway cells of patients with class I mutations KB407 transduction confirmed in all six patients with successful bronchoscopies irrespective of modulator-status; percentage of conducting airway cells transduced in each patient ranged from 29.4% to 42.1% Registrational repeat dosing CORAL-3 study design submitted to FDA in late December; anticipating enrollment in study to start in 1H 2026 following alignment with the FDA Investor call to be held January 8 at 4:30 pm ET to discuss data update and timelines for KB407 repeat dosing study start PITTSBURGH, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the "Company"
PITTSBURGH, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the "Company") (NASDAQ:KRYS) today announced that it will host an investor conference call and webcast tomorrow, Thursday, January 8, 2026, at 4:30 pm ET, to disclose an interim clinical update from CORAL-1, the Company's multi-center, dose escalation Phase 1 study evaluating KB407 in patients with cystic fibrosis. The interim clinical update will focus on results from patients in the highest dose cohort of CORAL-1 and include molecular assessments of KB407 transduction and wild-type cystic fibrosis transmembrane conductance regulator (CFTR) protein expression following inhaled administration of KB407. Investors and the
PITTSBURGH, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the "Company") (NASDAQ:KRYS) today announced that the Company will participate in the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026, in San Francisco. Krish S. Krishnan, Chairman and Chief Executive Officer, is scheduled to give a presentation at 10:30 am ET / 7:30 am PT and host investor meetings throughout the day. A webcast of the presentation will be available here beginning at 10:30 am ET / 7:30 am PT on Monday, January 12, 2026 and will be posted on the Investors section of the Company's website. About Krystal Biotech, Inc. Krystal Biotech, Inc. (NASDAQ:KRYS) is a fully integrated, commercial-
PITTSBURGH, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the "Company") (NASDAQ:KRYS) today announced that the Company will participate in the 8th Annual Evercore Healthcare Conference on December 3, 2025, in Miami. Krish S. Krishnan, Chairman and Chief Executive Officer, will take part in a fireside chat scheduled at 10:00 am ET and host investor meetings throughout the day. A webcast of the presentation will be available here beginning at 10:00 am ET on Wednesday, December 3, 2025 and will be posted on the Investors section of the Company's website. About Krystal Biotech, Inc. Krystal Biotech, Inc. (NASDAQ:KRYS) is a fully integrated, commercial-stage, global biotechnology
$97.8 million in 3Q VYJUVEK revenue and $623.2 million since U.S. launch VYJUVEK launched in Germany in 3Q; launched in France and Japan in 4Q Updated U.S. VYJUVEK label expands eligible patient population and provides greater patient flexibility FDA grants platform technology designation CF interim results expected in 4Q Strong balance sheet, ending the quarter with $864.2 million in cash and investments PITTSBURGH, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the "Company") (NASDAQ:KRYS) today reported financial results for the third quarter ending September 30, 2025 and provided a business update. "It is immensely gratifying to see a growing number of DEB patients w
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Citigroup upgraded Krystal Biotech from Neutral to Buy and set a new price target of $309.00
Jefferies initiated coverage of Krystal Biotech with a rating of Buy and set a new price target of $245.00
Citigroup downgraded Krystal Biotech from Buy to Neutral and set a new price target of $204.00 from $195.00 previously
Goldman initiated coverage of Krystal Biotech with a rating of Buy and set a new price target of $160.00
Cantor Fitzgerald initiated coverage of Krystal Biotech with a rating of Overweight and set a new price target of $100.00
Citigroup initiated coverage of Krystal Biotech with a rating of Buy and set a new price target of $160.00
Berenberg initiated coverage of Krystal Biotech with a rating of Buy and set a new price target of $154.00
Stifel initiated coverage of Krystal Biotech with a rating of Buy and set a new price target of $102.00
Goldman upgraded Krystal Biotech from Neutral to Buy and set a new price target of $124.00 from $79.00 previously
Goldman downgraded Krystal Biotech from Buy to Neutral and set a new price target of $74.00
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - Krystal Biotech, Inc. (0001711279) (Issuer)
4 - Krystal Biotech, Inc. (0001711279) (Issuer)
4 - Krystal Biotech, Inc. (0001711279) (Issuer)
4 - Krystal Biotech, Inc. (0001711279) (Issuer)
4 - Krystal Biotech, Inc. (0001711279) (Issuer)
4 - Krystal Biotech, Inc. (0001711279) (Issuer)
4 - Krystal Biotech, Inc. (0001711279) (Issuer)
4 - Krystal Biotech, Inc. (0001711279) (Issuer)
4 - Krystal Biotech, Inc. (0001711279) (Issuer)
4 - Krystal Biotech, Inc. (0001711279) (Issuer)
144 - Krystal Biotech, Inc. (0001711279) (Subject)
144 - Krystal Biotech, Inc. (0001711279) (Subject)
144 - Krystal Biotech, Inc. (0001711279) (Subject)
144 - Krystal Biotech, Inc. (0001711279) (Subject)
144 - Krystal Biotech, Inc. (0001711279) (Subject)
144 - Krystal Biotech, Inc. (0001711279) (Subject)
8-K - Krystal Biotech, Inc. (0001711279) (Filer)
10-K - Krystal Biotech, Inc. (0001711279) (Filer)
8-K - Krystal Biotech, Inc. (0001711279) (Filer)
8-K - Krystal Biotech, Inc. (0001711279) (Filer)
Live Leadership Updates
PITTSBURGH, April 07, 2025 (GLOBE NEWSWIRE) -- Jeune Aesthetics, Inc. ("Jeune"), a wholly owned subsidiary of Krystal Biotech, Inc. ("Krystal") (NASDAQ:KRYS) leveraging Krystal's clinically validated gene-delivery platform to fundamentally address and reverse the biology of aging skin, announced today the appointment of Marc Forth as Chief Executive Officer (CEO), effective today. A veteran of the healthcare industry, Mr. Forth has over 30 years of commercial and executive leadership experience, with an extensive track record of building innovative companies as well as launching and commercializing leading brands, including BOTOX®, one of the most widely recognized global brands. Mr. Forth
PITTSBURGH, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Jeune Aesthetics, Inc. ("Jeune"), a wholly owned subsidiary of Krystal Biotech, Inc. ("Krystal") (NASDAQ:KRYS) leveraging Krystal's clinically validated gene-delivery platform to fundamentally address and reverse the biology of aging skin, announced today the appointment of Nishant Saxena as Chief Financial Officer (CFO), effective January 15, 2025. Mr. Saxena has over 20 years of experience in finance, strategy, capital markets, mergers and acquisitions, and corporate development. Most recently, he was a Managing Director in Evercore's healthcare group, where he advised on transactions totaling over $500 billion in aggregate value. "It is my
NEW YORK, June 7, 2024 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, June 24, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P SmallCap 600 are more representative of the small-cap market space. The companies being removed from the S
-- Hubert Chen, accomplished drug developer and pharma executive, joins as Chief Medical Officer -- Industry veterans and leading academic experts joined Attovia's Clinical and Scientific Advisory Boards: Jonathan Silverberg, M.D., Ph.D., M.P.H., Lawrence Eichenfield, M.D., Brian Kim, M.D., MTR, Sonja Ständer, M.D., Dedee Murrell, M.D., D.Sc., Richard Heyman, Ph.D., Luisa Salter-Cid, Ph.D., and David King, Ph.D. FREMONT, Calif., March 26, 2024 (GLOBE NEWSWIRE) -- Attovia Therapeutics today announced the appointment of Hubert Chen, M.D., MPH, as Chief Medical Officer, effective March 21, 2024. Dr. Chen brings extensive clinical and industry leadership experience in drug develo
Karen Sims, MD, PhD Promoted to Chief Medical Officer Christopher Naftzger Appointed as General Counsel and Chief Compliance Officer WARMINSTER, Pa., July 10, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (NASDAQ:ABUS) ("Arbutus" or the "Company"), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced the appointment of Dr. Karen Sims as Chief Medical Officer and Mr. Christopher Naftzger as General Counsel and Chief Compliance Officer. Mr. Naftzger succeeds Dr. Elizabeth Howard who will continue in an advisory role with respect to the on-going patent infringement l
PITTSBURGH, March 06, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the "Company") (NASDAQ:KRYS) a biotechnology company focused on developing and commercializing genetic medicines for patients with rare diseases, today announced the appointment of Catherine Mazzacco to its Board of Directors. "I am pleased to welcome Catherine to our Board of Directors at this crucial next stage of Krystal's evolution," said Krish S. Krishnan, Chairman and Chief Executive Officer of Krystal Biotech, Inc. "As a seasoned executive with extensive valuable pharmaceutical and biotechnology industry experience, I look forward to Catherine's involvement and assistance in guiding our strategic objectives." "A
PITTSBURGH, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc., ("Krystal") (NASDAQ:KRYS), the leader in redosable gene therapies for rare disease, announced today the appointments of Jing Marantz as Chief Business Officer and Rand Sutherland as a new member of the Board of Directors. Dr. Marantz is an experienced biopharmaceutical industry executive who has held senior level positions in medical affairs, business development, and commercial strategy in multiple therapeutic areas, including rare diseases. Dr. Sutherland is a pulmonologist by training with deep clinical knowledge combined with R&D and corporate strategy leadership across pulmonary and rare diseases. In connection with
PITTSBURGH, Sept. 15, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc., ("Krystal") (NASDAQ:KRYS), the leader in redosable gene therapies for rare diseases, today announced the appointment of Laurent Goux as the General Manager of Europe. Mr. Goux has more than 20 years of global biotechnology experience, including serving as the Head of Global Strategic Marketing and Market Access at Galderma. "We are excited to welcome Laurent to the Krystal team at such a pivotal time for our lead investigational program, B-VEC for DEB, and the rest of our growing rare disease pipeline," said Andy Orth, Chief Commercial Officer of Krystal Biotech. "He is an accomplished executive who has successfully lau
PITTSBURGH, May 03, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., ("Krystal") (NASDAQ:KRYS), the leader in redosable gene therapies for rare diseases, announced today the appointment of Andy Orth as Chief Commercial Officer. Mr. Orth has more than 25 years of global biotechnology experience, most recently in the role of Senior Vice President, Head of US Business at Alnylam Pharmaceuticals. "We are excited to welcome Andy to the Krystal team at such an exciting time for our lead investigational program B-VEC for DEB, and the rest of our growing rare disease pipeline," said Krish S. Krishnan, chairman and chief executive officer of Krystal Biotech. "He is an accomplished biotechnology exec
PITTSBURGH--(BUSINESS WIRE)--Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases today announced the appointment of Chris Mason, MD, PhD, FRCS, FMedSci, and Jing L. Marantz, MD, PhD, MBA to its board of directors. “We are pleased to welcome Drs. Mason and Marantz to our board of directors,” said Krish S. Krishnan, Chairman and Chief Executive Officer of Krystal Biotech, Inc. “They bring significant gene therapy translational and rare disease commercial strategy expertise that will be invaluable as we continue on our mission to be a fully integrated rare disease company.” Dr. Mason is a Founder and Chief Scientific Officer at
This live feed shows all institutional transactions in real time.
SC 13G/A - Krystal Biotech, Inc. (0001711279) (Subject)
SC 13G/A - Krystal Biotech, Inc. (0001711279) (Subject)
SC 13G - Krystal Biotech, Inc. (0001711279) (Subject)
SC 13G/A - Krystal Biotech, Inc. (0001711279) (Subject)
SC 13G/A - Krystal Biotech, Inc. (0001711279) (Subject)
SC 13G/A - Krystal Biotech, Inc. (0001711279) (Subject)
SC 13G/A - Krystal Biotech, Inc. (0001711279) (Subject)
SC 13G - Krystal Biotech, Inc. (0001711279) (Subject)
SC 13G/A - Krystal Biotech, Inc. (0001711279) (Subject)
SC 13G/A - Krystal Biotech, Inc. (0001711279) (Subject)
Live finance-specific insights
$107.1 million in 4Q VYJUVEK revenue and $730.3 million since U.S. launch FDA granted RMAT to KB707 for the treatment of advanced NSCLC and Fast Track Designation to KB111 for the treatment of HHD Strong balance sheet, ending the quarter with $955.9 million in cash and investments PITTSBURGH, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the "Company") (NASDAQ:KRYS) today reported financial results for the fourth quarter and full year ending December 31, 2025 and provided a business update. "In 2025, Krystal made meaningful progress on our mission to serve patients with dystrophic epidermolysis bullosa around the world, while continuing to build the global infrastructure req
PITTSBURGH, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the "Company") (NASDAQ:KRYS) announced today that it will report its fourth quarter and full year 2025 financial results on Tuesday, February 17, 2026, prior to the open of U.S. markets. The Company's management will also host a conference call and webcast at 8:30 am ET on Tuesday, February 17, 2026, to discuss the financial results and provide a business update. Investors and the general public can access the live webcast at: https://www.webcaster5.com/Webcast/Page/3018/53598. For those unable to listen to the live webcast, a replay will be available for at least 30 days on the Investors section of the Company's websi
Confirmed wild-type CFTR delivery and expression in conducting airway cells of patients with class I mutations KB407 transduction confirmed in all six patients with successful bronchoscopies irrespective of modulator-status; percentage of conducting airway cells transduced in each patient ranged from 29.4% to 42.1% Registrational repeat dosing CORAL-3 study design submitted to FDA in late December; anticipating enrollment in study to start in 1H 2026 following alignment with the FDA Investor call to be held January 8 at 4:30 pm ET to discuss data update and timelines for KB407 repeat dosing study start PITTSBURGH, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the "Company"
PITTSBURGH, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the "Company") (NASDAQ:KRYS) today announced that it will host an investor conference call and webcast tomorrow, Thursday, January 8, 2026, at 4:30 pm ET, to disclose an interim clinical update from CORAL-1, the Company's multi-center, dose escalation Phase 1 study evaluating KB407 in patients with cystic fibrosis. The interim clinical update will focus on results from patients in the highest dose cohort of CORAL-1 and include molecular assessments of KB407 transduction and wild-type cystic fibrosis transmembrane conductance regulator (CFTR) protein expression following inhaled administration of KB407. Investors and the
$97.8 million in 3Q VYJUVEK revenue and $623.2 million since U.S. launch VYJUVEK launched in Germany in 3Q; launched in France and Japan in 4Q Updated U.S. VYJUVEK label expands eligible patient population and provides greater patient flexibility FDA grants platform technology designation CF interim results expected in 4Q Strong balance sheet, ending the quarter with $864.2 million in cash and investments PITTSBURGH, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the "Company") (NASDAQ:KRYS) today reported financial results for the third quarter ending September 30, 2025 and provided a business update. "It is immensely gratifying to see a growing number of DEB patients w
PITTSBURGH, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the "Company") (NASDAQ:KRYS) announced today that it will report its third quarter 2025 financial results on Monday, November 3, 2025, prior to the open of U.S. markets. The Company's management will also host a conference call and webcast at 8:30 am ET on Monday, November 3, 2025, to discuss the financial results and provide a business update. Investors and the general public can access the live webcast at: https://www.webcaster5.com/Webcast/Page/3018/53113. For those unable to listen to the live webcast, a replay will be available for at least 30 days on the Investors section of the Company's website at www.krystalbi
$96.0 million in 2Q VYJUVEK revenue and $525.4 million since launch in 3Q 2023 VYJUVEK approved in Japan for the treatment of DEB patients from birth Strong balance sheet, ending the quarter with $820.8 million in cash and investments PITTSBURGH, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the "Company") (NASDAQ:KRYS) today reported financial results for the second quarter ending June 30, 2025 and provided a business update. "With the approval of VYJUVEK in Europe and Japan, we are on the cusp of a global expansion that will build on our U.S. sales momentum and dramatically expand VYJUVEK access to DEB patients around the world," said Krish S. Krishnan, Cha
PITTSBURGH, July 29, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the "Company") (NASDAQ:KRYS), a commercial-stage biotechnology company, today announced that it will report its second quarter 2025 financial results on Monday, August 4, 2025, prior to the open of U.S. markets. The Company's management will also host a conference call and webcast at 8:30 am ET on Monday, August 4, 2025, to discuss the financial results and provide a business update. Investors and the general public can access the live webcast at: https://www.webcaster4.com/Webcast/Page/3018/52772. For those unable to listen to the live webcast, a replay will be available for at least 30 days on the Investors section o
KB304 designed to deliver collagen and elastin to restore skin naturally Conference call to discuss results scheduled for Thursday, July 24, 2025 at 4:30pm ET PITTSBURGH, July 24, 2025 (GLOBE NEWSWIRE) -- Jeune Aesthetics, Inc. ("Jeune"), a wholly owned subsidiary of Krystal Biotech, Inc. ("Krystal") (NASDAQ:KRYS) leveraging Krystal's clinically validated gene-delivery platform to fundamentally reverse the biology of aging skin, announced today positive safety and efficacy results, including significant improvements in key skin aesthetic attributes such as wrinkles and elasticity, in PEARL-2, a randomized, double-blind, placebo-controlled Phase 1 study evaluating KB30
Eye drop administration of KB801 designed to enable sustained expression of NGF in the front of the eye Investor call and webcast to be held July 9 at 8:30 am ET to discuss program and trial design PITTSBURGH, July 09, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the "Company") (NASDAQ:KRYS) announced today that the first patient has been dosed in its Phase 1/2 clinical trial ("EMERALD-1"), a 2:1 randomized, double-masked, multicenter, placebo-controlled study evaluating KB801 for the treatment of neurotrophic keratitis (NK). "Our ophthalmology pipeline is well under way with the dosing of our first patient in EMERALD-1, along with initiation of our Phase 3 IOLITE study in DEB," said